new YORK (Reuters Health) – the pharmaceutical Eli Lilly and

Co announced that its experimental drug against Alzheimer’s

it slowed the decline cognitive in patients with an initial degree

disease, although failed in the main objectives

assay clinical.

Lilly statement generated an increase of more than 8 by

cent in the shares of the company, before the hope that

new treatment can even deliver positive results.

the final stages of the clinical experiment, known as

EXPEDITION assessed the solanezumab in patients 1 and 2, with the

Alzheimer’s disease in mild to moderate stages, frente a

a placebo.

secondary outcomes analysis showed a

significant slowdown of cognitive decline in

patients with mild Alzheimer’s disease, but not in those who suffered of the

enfermage to a moderate degree, said the company.

“recognize that the solanezumab studies failed to

their primary objectives, but excite us data

accumulated that they seem to show a slowdown of the

cognitive decline”, said John Lechleiter, President

Executive of Lilly.

“we intend to treat these data with the

regulatory authorities to obtain their comments on

potential to follow steps”, added the Executive.

results reinforced expectations that essay

can still be viable if it is evaluated in patients who are

at an early stage of the disease, or those who do not come to

show symptoms.

the Lilly Drug aims to reduce levels of a

toxic protein that is found in the brains of patients with

Alzheimer’s called beta amyloid.

< p> Pfizer Inc and Johnson & Johnson said this month that a

similar drug developed, the bapineuzumab, not

managed to improve memory in the final stages of the

trials for patients in stages mild or moderate evil.

Tim Anderson, an analyst for Sanford Bernstein, said that

Friday results offer foundations theory of

that these treatments “probably need apply as

before during the course of the disease”.

“at this time, in theory, all possibilities are still

in game”, Anderson pointed out in a note of research.

patients who took the drug also

experienced adverse effects such as lethargy, rashes,

malaise and angina, compared to placebo, said Lilly.

El Alzheimer’s disease is the most common form of dementia and the

sixth belangrijke oorzaken van dood in de Verenigde Staten. ongeveer 5

miljoen Amerikanen lijden aan de ziekte, volgens

schattingen.

farmaceutische onderneming verklaarde dat zij de gegevens met zal bespreken

regelgevende autoriteiten.

Lilly aandelen bevorderen van 2,75 procent tot 43,59

dollar aan de 1444 GMT op de New York Stock Exchange.